Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1999
Business Overview: The Company operates primarily in the animal health sector, focusing on dairy and beef industries. Key products include "First Defense" and the "Kamar Heatmount Detector," which accounted for 95% of product sales. The Company also maintains a joint venture, AgriCell Company, LLC, for manufacturing bovine lactoferrin.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1999 | Six Months Ended June 30, 1998 |
|---|---|---|
| Total Revenues | $2,446,728 | $2,191,422 |
| Net Profit | $332,882 | $139,028 |
| Operating Income | $342,637 | $116,888 |
| Cash and Cash Equivalents (Ending) | $1,748,035 | $1,352,379 |
| Net Cash Provided by Operating Activities | $244,373 | $439,194 |
| Total Debt (Current + Long Term) | $462,107 | $470,606 |
| Working Capital | $2,236,384 | $1,866,222 |
| Stockholders' Equity | $2,580,478 | $2,247,596 |
Margins: Gross margin on product sales was 55% for the six-month period ended June 30, 1999, consistent with the prior year period. Research and development expenses represented 17% of total revenues for the six months ended June 30, 1999.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by approximately 12% ($255,306) compared to the six-month period in 1998. Product sales rose 11% ($227,000), driven by a 10% increase in sales of core products (First Defense and Kamar Heatmount Detector).
- Profitability: Net profit increased significantly by 139% ($193,854) year-over-year. Operating income more than doubled, rising from $116,888 to $342,637.
- Expense Management: General and administrative expenses decreased by 29% ($85,244) due to a management reorganization in December 1998. Research and development expenses remained relatively flat, increasing only 1% ($5,931).
- Liquidity: Cash and cash equivalents increased by $209,130. Net working capital improved by $370,162.
- Joint Venture: The Company recorded a non-cash charge of approximately $19,130 against its equity interest in AgriCell due to lower-than-expected lactoferrin sales linked to financial crises in South Korea and Japan.
Guidance, Outlook, and Risks
- Outlook: Management anticipates recording a profit for the full year ended December 31, 1999, contrasting with the net loss of $103,000 recorded for the full year 1998. This expectation is based on a strategic shift to focus on animal health products, which have lower funding requirements than previous human health programs.
- Capital Resources: The Company believes it has sufficient capital to meet working capital requirements for the next twelve months. Approximately $137,000 remains available under a Phase II Small Business Innovation Research grant to fund development expenses.
- Year 2000 Issue: The Company estimates total costs to address Year 2000 compliance will not exceed $23,000. Necessary software and hardware replacements have been identified and installed, with implementation continuing through the third quarter of 1999. Risks associated with third-party failures are deemed not material.
- Risks: Forward-looking statements are subject to risks regarding product development delays, regulatory approvals, and market competition. The joint venture's performance remains sensitive to international market conditions.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of sales given that 95% of product sales rely on two specific products (First Defense and Kamar Heatmount Detector).
- Joint Venture Valuation: Assess the impact of the $19,130 non-cash charge and the continued underperformance of the AgriCell lactoferrin facility on future earnings.
- Debt Obligations: Review the mortgage loan terms ($462,107 outstanding at 8.62% interest) and the balloon payment structure due in 2003.
- Grant Dependency: Confirm the timeline and utilization of the remaining $137,000 in SBIR grant funds and the potential for future government funding.
- Expense Trends: Monitor if the reduction in General and Administrative expenses is sustainable or if it was a one-time benefit of the 1998 reorganization.